{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:53:09Z","timestamp":1787964789336,"version":"build-2784847793"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-024-01470-5","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T09:02:19Z","timestamp":1724835739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Viral vector-based therapeutic HPV vaccines"],"prefix":"10.1007","volume":"24","author":[{"given":"Teng","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanfen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"1","key":"1470_CR1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","volume":"324","author":"EM De Villiers","year":"2004","unstructured":"De Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur HH. Classification of papillomaviruses. Virology. 2004;324(1):17\u201327.","journal-title":"Virology"},{"issue":"4","key":"1470_CR2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.20892\/j.issn.2095-3941.2020.0370","volume":"17","author":"KA Szymonowicz","year":"2020","unstructured":"Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020;17(4):864.","journal-title":"Cancer Biol Med"},{"issue":"9","key":"1470_CR3","doi-asserted-by":"crossref","first-page":"e1345","DOI":"10.1016\/S2214-109X(23)00305-4","volume":"11","author":"L Bruni","year":"2023","unstructured":"Bruni L, Albero G, Rowley J, Alemany L, Arbyn M, Giuliano AR, Markowitz LE, Broutet N, Taylor M. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis. Lancet Glob Health. 2023;11(9):e1345\u201362.","journal-title":"Lancet Glob Health"},{"issue":"10316","key":"1470_CR4","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","volume":"398","author":"M Falcaro","year":"2021","unstructured":"Falcaro M, Casta\u00f1on A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, Elliss-Brookes L, Sasieni P. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084\u201392.","journal-title":"Lancet"},{"issue":"14","key":"1470_CR5","doi-asserted-by":"crossref","first-page":"1150238","DOI":"10.3389\/fimmu.2023.1150238","volume":"12","author":"N Ebrahimi","year":"2023","unstructured":"Ebrahimi N, Yousefi Z, Khosravi G, Malayeri FE, Golabi M, Askarzadeh M, Shams MH, Ghezelbash B, Eskandari N. Human papillomavirus vaccination in low-and middle-income countries: progression, barriers, and future prospective. Front Immunol. 2023;12(14):1150238.","journal-title":"Front Immunol"},{"key":"1470_CR6","unstructured":"Doe J, Title of subordinate document. In: WHO preferred product characteristics for therapeutic HPV vaccines.World Health Organization. 2024. https:\/\/www.who.int\/publications\/iitem\/9789240092174. Accessed 3 July 2024"},{"issue":"10","key":"1470_CR7","volume":"13","author":"AI Khalil","year":"2023","unstructured":"Khalil AI, Zhang L, Muwonge R, Sauvaget C, Basu P. Efficacy and safety of therapeutic HPV vaccines to treat CIN 2\/CIN 3 lesions: a systematic review and meta-analysis of phase II\/III clinical trials. BMJ Open. 2023;13(10): e069616.","journal-title":"BMJ Open"},{"issue":"3","key":"1470_CR8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/vaccines12030228","volume":"12","author":"F \u0218andru","year":"2024","unstructured":"\u0218andru F, Radu AM, Petca A, Dumitra\u0219cu MC, Petca RC, Roman AM. Unveiling the therapeutic horizon: hpv vaccines and their impact on cutaneous diseases\u2014a comprehensive review. Vaccines. 2024;12(3):228.","journal-title":"Vaccines"},{"issue":"3","key":"1470_CR9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/cancers16030672","volume":"16","author":"CA Goncalves","year":"2024","unstructured":"Goncalves CA, Pereira-da-Silva G, Silveira RC, Mayer PC, Zilly A, Lopes-Junior LC. Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2\/3) associated with human papillomavirus: a systematic review. Cancers. 2024;16(3):672.","journal-title":"Cancers"},{"key":"1470_CR10","first-page":"122331","volume":"7","author":"R Poria","year":"2023","unstructured":"Poria R, Kala D, Nagraik R, Dhir Y, Dhir S, Singh B, Kaushik NK, Noorani MS, Kaushal A, Gupta S. Vaccine development: current trends and technologies. Life Sci. 2023;7:122331.","journal-title":"Life Sci"},{"issue":"8","key":"1470_CR11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14760584.2019.1640117","volume":"18","author":"JL Excler","year":"2019","unstructured":"Excler JL, Kim JH. Novel prime-boost vaccine strategies against HIV-1. Expert Rev Vacc. 2019;18(8):765\u201379.","journal-title":"Expert Rev Vacc"},{"issue":"12","key":"1470_CR12","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/S1473-3099(23)00344-4","volume":"23","author":"B Mwesigwa","year":"2023","unstructured":"Mwesigwa B, Houser KV, Hofstetter AR, Ortega-Villa AM, Naluyima P, Kiweewa F, Nakabuye I, Yamshchikov GV, Andrews C, O\u2019Callahan M, Strom L. Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial. Lancet Inf Dis. 2023;23(12):1408\u201317.","journal-title":"Lancet Inf Dis."},{"issue":"2","key":"1470_CR13","doi-asserted-by":"crossref","first-page":"2234784","DOI":"10.1080\/21645515.2023.2234784","volume":"19","author":"AE Ralise","year":"2023","unstructured":"Ralise AE, Camargo TM, Marson FA. Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination. Human Vacc Immunotherap. 2023;19(2):2234784.","journal-title":"Human Vacc Immunotherap."},{"issue":"10","key":"1470_CR14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.medj.2023.07.003","volume":"4","author":"SE Silk","year":"2023","unstructured":"Silk SE, Kalinga WF, Mtaka IM, Lilolime NS, Mpina M, Milando F, Ahmed S, Diouf A, Mkwepu F, Simon B, Athumani T. Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults. Med. 2023;4(10):668\u201386.","journal-title":"Med"},{"issue":"1","key":"1470_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41541-021-00348-x","volume":"6","author":"MY Lee","year":"2021","unstructured":"Lee MY, Metenou S, Brough DE, Sabzevari H, Bai K, Jochems C, Schlom J, Allen CT. Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis. NPJ Vacc. 2021;6(1):86. https:\/\/doi.org\/10.1038\/s41541-021-00348-x.","journal-title":"NPJ Vacc"},{"issue":"12","key":"1470_CR16","first-page":"3676","volume":"8","author":"AM Kaufmann","year":"2002","unstructured":"Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clinical Cancer Res Off J Ame Assoc Cancer Res. 2002;8(12):3676\u201385.","journal-title":"Clinical Cancer Res Off J Ame Assoc Cancer Res"},{"key":"1470_CR17","unstructured":"Turnstone Biologics C. Phase 1\/1b, Multicenter, Open-label Trial of Oncolytic MG1 Virus (MG1-E6E7) With Adenovirus Vaccine (Ad-E6E7) Both Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 and Atezolizumab in Pts With HPV Assoc. Cancers. ClinicalTrials.gov; 2023 Apr[cited 20 Mar 2024].Report No.NCT03618953.Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03618953."},{"issue":"191","key":"1470_CR18","doi-asserted-by":"crossref","first-page":"112981","DOI":"10.1016\/j.ejca.2023.112981","volume":"1","author":"E Borcoman","year":"2023","unstructured":"Borcoman E, Lalanne A, Delord JP, Cassier PA, Rolland F, Salas S, Limacher JM, Capitain O, Lantz O, Ekwegbara C, Jeannot E. Phase Ib\/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers. Eur J Cancer. 2023;1(191):112981.","journal-title":"Eur J Cancer"},{"key":"1470_CR19","unstructured":"Groningen UMC. A Phase II Study to Determine the Efficacy and Safety of Vvax001, a Therapeutic Semliki Forest Virus Based Cancer Vaccine, in Patients With HPV-16 Induced Grade 3 Cervical Intraepithelial Neoplasia. ClinicalTrials.gov; 2023 Aug[cited 20 Mar 2024].Report No.NCT06015854.Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06015854."},{"issue":"16","key":"1470_CR20","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1200\/JCO.2023.41.16_suppl.2628","volume":"41","author":"CS Floudas","year":"2023","unstructured":"Floudas CS, Floudas JSJM. Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent\/metastatic (R\/M) HPV-associated cancers (HPV-C). J Clin Oncol. 2023;41(16):2628. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.2628.","journal-title":"J Clin Oncol"},{"key":"1470_CR21","unstructured":"Biotherapeutics B. A Phase 1b\/2, Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-Vectored Multigenotype High Risk Human Papillomavirus (hrHPV) Vaccine and Modified Vaccinia Ankara (MVA)-Vectored Multigenotype hrHPV Vaccine in Women With Low-grade HPV-related Cervical Lesions. ClinicalTrials.gov; 2024 Jan[cited 20 Mar 2024].Report No.NCT04607850.Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04607850."},{"key":"1470_CR22","unstructured":"GmbH HB. A Phase I\/II Study of TheraT\u00ae Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers. ClinicalTrials.gov; 2024 Mar[cited 20 Mar 2024].Report No.NCT04180215.Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04180215."},{"key":"1470_CR23","unstructured":"JVPB V, Randomized A. Double-blind, Placebo-controlled, First-in-Human, Phase 1\/2a Study to Evaluate Safety, Reactogenicity and Immunogenicity of Monovalent HPV16 and HPV18 Ad26-vectored Vaccine Components and an MVA-vectored HPV16\/18 Vaccine Component in Otherwise Healthy Women With HPV16 or 18 Infection of the Cervix. ClinicalTrials.gov; 2021 Nov[cited 20 Mar 2024].Report No.NCT03610581.Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03610581."},{"issue":"4","key":"1470_CR24","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","volume":"141","author":"C De Martel","year":"2017","unstructured":"De Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664\u201370.","journal-title":"Int J Cancer"},{"key":"1470_CR25","unstructured":"WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. Geneva: World Health Organization; 2021."},{"issue":"1","key":"1470_CR26","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1186\/s12885-023-11697-2","volume":"23","author":"L Kong","year":"2023","unstructured":"Kong L, Xiao X, Xu T, Wan R, Chen F. Immediate histologic correlation in patients with different HPV genotypes and ages: a single center analysis in China. BMC Cancer. 2023;23(1):1211.","journal-title":"BMC Cancer"},{"issue":"7","key":"1470_CR27","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.24116","volume":"124","author":"H De Vuyst","year":"2009","unstructured":"De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124(7):1626\u201336.","journal-title":"Int J Cancer"},{"issue":"4","key":"1470_CR28","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0002-9440(10)62506-0","volume":"159","author":"MA Rubin","year":"2001","unstructured":"Rubin MA, Kleter B, Zhou M, Ayala G, Cubilla AL, Quint WG, et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol. 2001;159(4):1211\u20138.","journal-title":"Am J Pathol"},{"issue":"5","key":"1470_CR29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.eururo.2015.12.007","volume":"69","author":"L Alemany","year":"2016","unstructured":"Alemany L, Cubilla A, Halec G, Kasamatsu E, Quir\u00f3s B, Masferrer E, Tous S, Lloveras B, Hern\u00e1ndez-Suarez G, Lonsdale R, Tinoco L. Role of human papillomavirus in penile carcinomas worldwide. Eur Urol. 2016;69(5):953\u201361.","journal-title":"Eur Urol"},{"issue":"12","key":"1470_CR30","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1470-2045(14)70471-1","volume":"15","author":"C Ndiaye","year":"2014","unstructured":"Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagu\u00e9 X, Laporte L, Bosch FX, de Sanjos\u00e9 S, Trottier H. HPV DNA, E6\/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15(12):1319\u201331.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1470_CR31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hed.22015","volume":"35","author":"H Mehanna","year":"2013","unstructured":"Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, Roberts S. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer\u2014systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35(5):747\u201355.","journal-title":"Head Neck"},{"issue":"2","key":"1470_CR32","first-page":"467","volume":"14","author":"AR Kreimer","year":"2005","unstructured":"Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Preven Publ Am Assoc Cancer ResCospon Am Soc Preven Oncol. 2005;14(2):467\u201375.","journal-title":"Cancer Epidemiol Biomark Preven Publ Am Assoc Cancer ResCospon Am Soc Preven Oncol."},{"issue":"2","key":"1470_CR33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-17-2335","volume":"24","author":"MP Morrow","year":"2018","unstructured":"Morrow MP, Kraynyak KA, Sylvester AJ, Dallas M, Knoblock D, Boyer JD, Yan J, Vang R, Khan AS, Humeau L, Sardesai NY. Clinical and immunologic biomarkers for histologic regression of high-grade cervical dysplasia and clearance of HPV16 and HPV18 after immunotherapy. Clin Cancer Res. 2018;24(2):276\u201394.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1470_CR34","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1042\/CS20050369","volume":"110","author":"J Doorbar","year":"2006","unstructured":"Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci. 2006;110(5):525\u201341.","journal-title":"Clin Sci"},{"issue":"11","key":"1470_CR35","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/jnci\/djp106","volume":"101","author":"S Jagu","year":"2009","unstructured":"Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. JNCI J National Cancer Instit. 2009;101(11):782\u201392. https:\/\/doi.org\/10.1093\/jnci\/djp106.","journal-title":"JNCI J National Cancer Instit"},{"issue":"12","key":"1470_CR36","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S1473-3099(22)00435-2","volume":"22","author":"FH Zhao","year":"2022","unstructured":"Zhao FH, Wu T, Hu YM, Wei LH, Li MQ, Huang WJ, Chen W, Huang SJ, Pan QJ, Zhang X, Hong Y. Efficacy, safety, and immunogenicity of an E. coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Lancet Infect Dis. 2022;22(12):1756\u201368.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"1470_CR37","doi-asserted-by":"crossref","first-page":"955847","DOI":"10.3389\/fcimb.2022.955847","volume":"28","author":"F Baedyananda","year":"2022","unstructured":"Baedyananda F, Sasivimolrattana T, Chaiwongkot A, Varadarajan S, Bhattarakosol P. Role of HPV16 E1 in cervical carcinogenesis. Front Cell Infect Microbiol. 2022;28(12):955847.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"1470_CR38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1074\/jbc.275.1.87","volume":"275","author":"K Webster","year":"2000","unstructured":"Webster K, Parish J, Pandya M, Stern PL, Clarke AR, Gaston K. The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV Proteins and via a p53-dependent Pathway. J Biol Chem. 2000;275(1):87\u201394.","journal-title":"J Biol Chem"},{"issue":"54","key":"1470_CR39","doi-asserted-by":"crossref","first-page":"7748","DOI":"10.1038\/sj.onc.1203208","volume":"18","author":"P Massimi","year":"1999","unstructured":"Massimi P, Pim D, Bertoli C, Bouvard V, Banks L. Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene. 1999;18(54):7748\u201354.","journal-title":"Oncogene"},{"issue":"12","key":"1470_CR40","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1089\/hum.2014.024","volume":"25","author":"R Rosales","year":"2014","unstructured":"Rosales R, L\u00f3pez-Contreras M, Rosales C, Magallanes-Molina J, Gonzalez-Vergara R, Arroyo-Cazarez JM, et al. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther. 2014;25(12):1035\u201349.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"1470_CR41","first-page":"611","volume":"191","author":"JL Pretet","year":"2007","unstructured":"Pretet JL, Charlot JF, Mougin C. Virological and carcinogenic aspects of HPV. Bull de L\u2019academie National de Med. 2007;191(3):611\u201323.","journal-title":"Bull de L'academie National de Med."},{"key":"1470_CR42","doi-asserted-by":"crossref","first-page":"47752","DOI":"10.1007\/s11356-021-15441-w","volume":"28","author":"N Ayesha","year":"2021","unstructured":"Ayesha N, Aboulaghras S, Jahangeer M, Riasat A, Ramzan R, Fatima R, Akram M, Balahbib A, Bouyahya A, Sepiashvili E, Zengin G. Physiopathology and effectiveness of therapeutic vaccines against human papillomavirus. Environ Sci Poll Res. 2021;28:47752\u201372.","journal-title":"Environ Sci Poll Res."},{"issue":"7587","key":"1470_CR43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature16481","volume":"529","author":"D Martinez-Zapien","year":"2016","unstructured":"Martinez-Zapien D, Ruiz FX, Poirson J, Mitschler A, Ramirez J, Forster A, Cousido-Siah A, Masson M, Pol SV, Podjarny A, Trave G. Structure of the E6\/E6AP\/p53 complex required for HPV-mediated degradation of p53. Nature. 2016;529(7587):541\u20135.","journal-title":"Nature"},{"issue":"6","key":"1470_CR44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.01737-17","volume":"92","author":"C Chiang","year":"2018","unstructured":"Chiang C, Pauli EK, Biryukov J, Feister KF, Meng M, White EA, M\u00fcnger K, Howley PM, Meyers C, Gack MU. The human papillomavirus E6 oncoprotein targets USP15 and TRIM25 To suppress RIG-I-mediated innate immune signaling. J Virol. 2018;92(6):10\u2013128.","journal-title":"J Virol"},{"issue":"10","key":"1470_CR45","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fmicb.2019.03116","volume":"21","author":"A Pal","year":"2020","unstructured":"Pal A, Kundu R. Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front Microbiol. 2020;21(10):3116.","journal-title":"Front Microbiol"},{"issue":"6","key":"1470_CR46","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJ, Bhardwaj N. Therapeutic cancer vaccines. Nature Rev Cancer. 2021;21(6):360\u201378.","journal-title":"Nature Rev Cancer."},{"issue":"9","key":"1470_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004790","volume":"10","author":"C Xiong","year":"2022","unstructured":"Xiong C, Huang L, Kou H, Wang C, Zeng X, Sun H, et al. Identification of of novel HLA-A*11:01-restricted HPV16 E6\/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy. J Immunother CanceR. 2022;10(9): e4790. https:\/\/doi.org\/10.1136\/jitc-2022-004790.","journal-title":"J Immunother CanceR"},{"issue":"1","key":"1470_CR48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12929-022-00864-5","volume":"29","author":"S Peng","year":"2022","unstructured":"Peng S, Xing D, Ferrall L, Tsai YC, Hung CF, Wu TC. Identification of human MHC-I HPV18 E6\/E7-specific CD8+ T cell epitopes and generation of an HPV18 E6\/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice. J Biomed Sci. 2022;29(1):80.","journal-title":"J Biomed Sci"},{"issue":"25\u201326","key":"1470_CR49","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1016\/j.vaccine.2009.01.080","volume":"27","author":"IG Ovsyannikova","year":"2009","unstructured":"Ovsyannikova IG, Vierkant RA, Pankratz VS, O\u2019Byrne MM, Jacobson RM, Poland GA. HLA haplotype and supertype associations with cellular immune responses and cytokine production in healthy children after rubella vaccine. Vaccine. 2009;27(25\u201326):3349\u201358.","journal-title":"Vaccine"},{"issue":"10","key":"1470_CR50","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/cgt.2012.55","volume":"19","author":"BG Wieking","year":"2012","unstructured":"Wieking BG, Vermeer DW, Spanos WC, Lee KM, Vermeer P, Lee WT, Xu Y, Gabitzsch ES, Balcaitis S, Balint JP, Jones FR. A non-oncogenic HPV 16 E6\/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther. 2012;19(10):667\u201374.","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"1470_CR51","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/hed.25477","volume":"41","author":"OR Cabo Beltran","year":"2019","unstructured":"Cabo Beltran OR, Rosales LR. MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis. Head Neck. 2019;41(3):657\u201365.","journal-title":"Head Neck"},{"issue":"6","key":"1470_CR52","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","volume":"13","author":"E Garcia-Hernandez","year":"2006","unstructured":"Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, Contreras ML, Padilla S, Guzman CC, Jimenez R, Reyes L, Morosoli G, Verde ML, Rosales R. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther. 2006;13(6):592\u20137.","journal-title":"Cancer Gene Ther"},{"issue":"52","key":"1470_CR53","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1016\/j.vaccine.2022.10.069","volume":"40","author":"W Qi","year":"2022","unstructured":"Qi W, Qingfeng L, Jing Z, Maolin Z, Zhihui Z, Wangqi D, Shanli Z, Jun C, Pengfei J, Lifang Z. A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model. Vaccine. 2022;40(52):7693\u2013702.","journal-title":"Vaccine"},{"issue":"7875","key":"1470_CR54","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41586-020-2931-3","volume":"597","author":"A Wieland","year":"2021","unstructured":"Wieland A, Patel MR, Cardenas MA, Eberhardt CS, Hudson WH, Obeng RC, Griffith CC, Wang X, Chen ZG, Kissick HT, Saba NF. Defining HPV-specific B cell responses in patients with head and neck cancer. Nature. 2021;597(7875):274\u20138.","journal-title":"Nature"},{"issue":"41","key":"1470_CR55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","volume":"1","author":"KJ Ewer","year":"2016","unstructured":"Ewer KJ, Lambe T, Rollier CS, Spencer AJ, Hill AV, Dorrell L. Viral vectors as vaccine platforms: from immunogenicity to impact. Current Opin Immunol. 2016;1(41):47\u201354.","journal-title":"Current Opin Immunol."},{"issue":"14","key":"1470_CR56","volume":"118","author":"S Yum","year":"2021","unstructured":"Yum S, Li M, Fang Y, Chen ZJ. TBK1 recruitment to STING activates both IRF3 and NF-\u03baB that mediate immune defense against tumors and viral infections. Procee National Acad Sci. 2021;118(14): e2100225118.","journal-title":"Procee National Acad Sci."},{"issue":"4","key":"1470_CR57","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","volume":"50","author":"HM Lazear","year":"2019","unstructured":"Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity. 2019;50(4):907\u201323.","journal-title":"Immunity"},{"key":"1470_CR58","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0083-6729(04)67014-2","volume":"67","author":"J Str\u00e4ter","year":"2004","unstructured":"Str\u00e4ter J, M\u00f6ller P. TRAIL and viral infection. Vitam Horm. 2004;67:257\u201374.","journal-title":"Vitam Horm"},{"issue":"11","key":"1470_CR59","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.bcp.2006.06.002","volume":"72","author":"M Solis","year":"2006","unstructured":"Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, Hiscott J. Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-tumor activity in primary macrophages. Biochem Pharmacol. 2006;72(11):1469\u201376.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"1470_CR60","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/cei.12785","volume":"185","author":"AB Bigley","year":"2016","unstructured":"Bigley AB, Rezvani K, Shah N, Sekine T, Balneger N, Pistillo M, Agha N, Kunz H, O\u2019Connor DP, Bollard CM, Simpson RJ. Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans. Clin Experimen Immunol. 2016;185(2):239\u201351.","journal-title":"Clin Experimen Immunol."},{"issue":"5","key":"1470_CR61","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","volume":"20","author":"GV Sharonov","year":"2020","unstructured":"Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nature Rev Immunol. 2020;20(5):294\u2013307.","journal-title":"Nature Rev Immunol."},{"issue":"7","key":"1470_CR62","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2207566","volume":"388","author":"AR Falsey","year":"2023","unstructured":"Falsey AR, Williams K, Gymnopoulou E, Bart S, Ervin J, Bastian AR, Menten J, De Paepe E, Vandenberghe S, Chan EK, Sadoff J. Efficacy and safety of an Ad26.RSV.preF-RSV preF protein vaccine in older adults. New Eng J Med. 2023;388(7):609\u201320.","journal-title":"New Eng J Med."},{"issue":"10240","key":"1470_CR63","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845\u201354.","journal-title":"Lancet"},{"issue":"10318","key":"1470_CR64","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","volume":"398","author":"AP Munro","year":"2021","unstructured":"Munro AP, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258\u201376.","journal-title":"Lancet"},{"issue":"8","key":"1470_CR65","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/infdis\/jiad108","volume":"228","author":"E Jordan","year":"2023","unstructured":"Jordan E, Kabir G, Schultz S, Silbernagl G, Schmidt D, Jenkins VA, Weidenthaler H, Stroukova D, Martin BK, De Moerlooze L. Reduced respiratory syncytial virus load, symptoms, and infections: a human challenge trial of MVA-BN-RSV vaccine. J Inf Dis. 2023;228(8):999\u20131011.","journal-title":"J Inf Dis"},{"key":"1470_CR66","volume":"172","author":"M Dumitrescu","year":"2021","unstructured":"Dumitrescu M, Trusca VG, Fenyo IM, Gafencu AV. An Efficient method for adenovirus production. JoVE J Visual Experiments. 2021;172: e61691.","journal-title":"JoVE J Visual Experiments."},{"issue":"15","key":"1470_CR67","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","volume":"77","author":"R Vogels","year":"2003","unstructured":"Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de B\u00e9thune M, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003;77(15):8263\u201371.","journal-title":"J Virol"},{"issue":"1","key":"1470_CR68","doi-asserted-by":"crossref","first-page":"6703","DOI":"10.1038\/s41467-023-42559-x","volume":"14","author":"M Aid","year":"2023","unstructured":"Aid M, Stephenson KE, Collier AR, Nkolola JP, Michael JV, McKenzie SE, Barouch DH. Activation of coagulation and proinflammatory pathways in thrombosis with thrombocytopenia syndrome and following COVID-19 vaccination. Nature Commun. 2023;14(1):6703.","journal-title":"Nature Commun"},{"issue":"8","key":"1470_CR69","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1172\/JCI9819","volume":"105","author":"MJ Mastrangelo","year":"2000","unstructured":"Mastrangelo MJ, Eisenlohr LC, Gomella L, Lattime EC. Poxvirus vectors: orphaned and underappreciated. J Clin Investig. 2000;105(8):1031\u20134.","journal-title":"J Clin Investig"},{"issue":"6","key":"1470_CR70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010658","volume":"18","author":"TP Monath","year":"2022","unstructured":"Monath TP, Nichols R, Tussey L, Scappaticci K, Pullano TG, Whiteman MD, Vasilakis N, Rossi SL, Campos RK, Azar SR, Spratt HM. Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential. PLoS Pathog. 2022;18(6): e1010658.","journal-title":"PLoS Pathog"},{"issue":"21","key":"1470_CR71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2016.06.001","volume":"1","author":"HC Ertl","year":"2016","unstructured":"Ertl HC. Viral vectors as vaccine carriers. Current Opin Virol. 2016;1(21):1\u20138.","journal-title":"Current Opin Virol."},{"issue":"3","key":"1470_CR72","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.yrtph.2006.01.002","volume":"44","author":"M Chabicovsky","year":"2006","unstructured":"Chabicovsky M, Ryle P. Non-clinical development of cancer vaccines: regulatory considerations. Regul Toxicol Pharmacol. 2006;44(3):226\u201337.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"1","key":"1470_CR73","first-page":"21","volume":"56","author":"KY Lin","year":"1996","unstructured":"Lin KY, Guarnieri FG, Staveley-O\u2019Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56(1):21\u20136.","journal-title":"Cancer Res"},{"issue":"9","key":"1470_CR74","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/eji.1830230929","volume":"23","author":"MC Feltkamp","year":"1993","unstructured":"Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993;23(9):2242\u20139.","journal-title":"Eur J Immunol"},{"issue":"18","key":"1470_CR75","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/0008-5472.CAN-18-0892","volume":"78","author":"S Dorta-Estremera","year":"2018","unstructured":"Dorta-Estremera S, Chin RL, Sierra G, Nicholas C, Yanamandra AV, Nookala SM, Yang G, Singh S, Curran MA, Sastry KJ. Mucosal HPV E6\/E7 peptide vaccination in combination with immune checkpoint modulation induces regression of HPV+ oral cancers. Cancer Res. 2018;78(18):5327\u201339.","journal-title":"Cancer Res"},{"issue":"1","key":"1470_CR76","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s42826-023-00166-3","volume":"39","author":"E Totain","year":"2023","unstructured":"Totain E, Lindner L, Martin N, Misseri Y, Ich\u00e9 A, Birling MC, Sorg T, Herault Y, Bousquet-Melou A, Bouill\u00e9 P, Duthoit C. Development of HPV16 mouse and dog models for more accurate prediction of human vaccine efficacy. Lab Anim Res. 2023;39(1):14.","journal-title":"Lab Anim Res"},{"issue":"10","key":"1470_CR77","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3389\/fmicb.2019.02093","volume":"10","author":"Z Chen","year":"2019","unstructured":"Chen Z, Long T, Wong PY, Ho WC, Burk RD, Chan PK. Non-human primate papillomaviruses share similar evolutionary histories and niche adaptation as the human counterparts. Front Microbiol. 2019;10(10):2093.","journal-title":"Front Microbiol"},{"issue":"1773","key":"1470_CR78","doi-asserted-by":"crossref","first-page":"20180294","DOI":"10.1098\/rstb.2018.0294","volume":"374","author":"NM Cladel","year":"2019","unstructured":"Cladel NM, Peng X, Christensen N, Hu J. The rabbit papillomavirus model: a valuable tool to study viral\u2013host interactions. Philosoph Trans Royal Soc B. 2019;374(1773):20180294.","journal-title":"Philosoph Trans Royal Soc B."},{"key":"1470_CR79","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1600-065X.1999.tb01377.x","volume":"172","author":"G S\u00f8nderstrup","year":"1999","unstructured":"S\u00f8nderstrup G, Cope AP, Patel S, Congia M, Hain N, Hall FC, et al. HLA class II transgenic mice: models of the human CD4+ T-cell immune response. Immunol Rev. 1999;172:335\u201343.","journal-title":"Immunol Rev"},{"key":"1470_CR80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-020-00700-8","volume":"28","author":"SH Tseng","year":"2021","unstructured":"Tseng SH, Liu L, Peng S, Kim J, Ferrall L, Hung CF, Wu TC. Control of spontaneous HPV16 E6\/E7 expressing oral cancer in HLA-A2 (AAD) transgenic mice with therapeutic HPV DNA vaccine. J Biomed Sci. 2021;28:1\u20132.","journal-title":"J Biomed Sci"},{"issue":"11","key":"1470_CR81","doi-asserted-by":"crossref","first-page":"784947","DOI":"10.3389\/fonc.2021.784947","volume":"18","author":"MM Cogels","year":"2021","unstructured":"Cogels MM, Rouas R, Ghanem GE, Martinive P, Awada A, Van Gestel D, Krayem M. Humanized mice as a valuable pre-clinical model for cancer immunotherapy research. Front Oncol. 2021;18(11):784947.","journal-title":"Front Oncol"},{"issue":"4","key":"1470_CR82","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/vaccines7040181","volume":"7","author":"G Tapia-Calle","year":"2019","unstructured":"Tapia-Calle G, Born PA, Koutsoumpli G, Gonzalez-Rodriguez MI, Hinrichs WL, Huckriede AL. A PBMC-based system to assess human T cell responses to influenza vaccine candidates in vitro. Vaccines. 2019;7(4):181.","journal-title":"Vaccines"},{"issue":"1","key":"1470_CR83","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-022-01515-x","volume":"21","author":"L Huang","year":"2022","unstructured":"Huang L, Rong Y, Tang X, Yi K, Qi P, Hou J, Liu W, He Y, Gao X, Yuan C, Wang F. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Mol Cancer. 2022;21(1):45.","journal-title":"Mol Cancer"},{"issue":"10","key":"1470_CR84","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1089\/hum.2018.091","volume":"29","author":"P Mercier-Letondal","year":"2018","unstructured":"Mercier-Letondal P, Marton C, Deschamps M, Ferrand C, Vauchy C, Chenut C, Baguet A, Adot\u00e9vi O, Borg C, Galaine J, Godet Y. Isolation and characterization of an HLA-DRB1* 04-restricted HPV16-E7 T cell receptor for cancer immunotherapy. Human Gene Ther. 2018;29(10):1202\u201312.","journal-title":"Human Gene Ther"},{"issue":"9","key":"1470_CR85","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s43018-022-00433-7","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu B, Zhang Y, Wang D, Hu X, Zhang Z. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade. Nature Cancer. 2022;3(9):1123\u201336.","journal-title":"Nature Cancer."},{"key":"1470_CR86","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1126\/scitranslmed.aaz1863","volume":"12","author":"AK Park","year":"2020","unstructured":"Park AK, Fong Y, Kim SI, Yang J, Murad JP, Lu J, et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci Transl MeD. 2020;12:1863. https:\/\/doi.org\/10.1126\/scitranslmed.aaz1863.","journal-title":"Sci Transl MeD"},{"issue":"21\u201322","key":"1470_CR87","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.vaccine.2004.01.049","volume":"22","author":"EJ Davidson","year":"2004","unstructured":"Davidson EJ, Faulkner RL, Sehr P, Pawlita M, Smyth LJ, Burt DJ, Tomlinson AE, Hickling J, Kitchener HC, Stern PL. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16\/18 E6E7). Vaccine. 2004;22(21\u201322):2722\u20139.","journal-title":"Vaccine"},{"issue":"3","key":"1470_CR88","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1525-1438.2006.00598.x","volume":"16","author":"AN Fiander","year":"2006","unstructured":"Fiander AN, Tristram AJ, Davidson EJ, Tomlinson AE, Man S, Baldwin PJ, et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer. 2006;16(3):1075\u201381. https:\/\/doi.org\/10.1111\/j.1525-1438.2006.00598.x.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"1470_CR89","doi-asserted-by":"crossref","first-page":"18713","DOI":"10.1038\/s41598-019-55014-z","volume":"9","author":"G Hancock","year":"2019","unstructured":"Hancock G, Blight J, Lopez-Camacho C, Kopycinski J, Pocock M, Byrne W, Price MJ, Kemlo P, Evans RI, Bloss A, Saunders K. A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins. Sci Rep. 2019;9(1):18713.","journal-title":"Sci Rep"},{"issue":"8","key":"1470_CR90","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/2159-8290.CD-20-1760","volume":"11","author":"AA Shamseddine","year":"2021","unstructured":"Shamseddine AA, Burman B, Lee NY, Zamarin D, Riaz N. Tumor immunity and immunotherapy for HPV-related cancers. Cancer Discov. 2021;11(8):1896\u2013912.","journal-title":"Cancer Discov"},{"key":"1470_CR91","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/jitc-2021-004022","volume":"10","author":"M Xiao","year":"2022","unstructured":"Xiao M, Xie L, Cao G, Lei S, Wang P, Wei Z, et al. CD4(+) Epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1\/PD-L1 immunotherapy. J Immun Cancer. 2022;10:5. https:\/\/doi.org\/10.1136\/jitc-2021-004022.","journal-title":"J Immun Cancer"},{"issue":"4","key":"1470_CR92","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/JLB.5BT0420-585RR","volume":"108","author":"S Roy","year":"2020","unstructured":"Roy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. Breakthrough concepts in immune-oncology: cancer vaccines at the bedside. J Leuc Biol. 2020;108(4):1455\u201389.","journal-title":"J Leuc Biol."},{"issue":"31","key":"1470_CR93","doi-asserted-by":"crossref","first-page":"S1442","DOI":"10.1016\/j.annonc.2020.10.551","volume":"1","author":"C Le Tourneau","year":"2020","unstructured":"Le Tourneau C, Cassier P, Rolland F, Salas S, Limacher JM, Capitain O, Lantz O, Lalanne A, Ekwegbara C, Tavernaro A, Makhloufi H. 63MO TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV)+ malignancies. Ann Oncol. 2020;1(31):S1442.","journal-title":"Ann Oncol"},{"issue":"12","key":"1470_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145260","volume":"10","author":"PB de Andrade","year":"2015","unstructured":"de Andrade PB, E. Maduro Bouillet L, Dorigo NA, Fraefel C, Bruna-Romero O. Adenovirus specific pre-immunity induced by natural route of infection does not impair transduction by adenoviral vaccine vectors in mice. PLoS ONE. 2015;10(12): e145260. https:\/\/doi.org\/10.1371\/journal.pone.0145260.","journal-title":"PLoS ONE"},{"issue":"300","key":"1470_CR95","doi-asserted-by":"publisher","first-page":"126r","DOI":"10.1126\/scitranslmed.aac5745","volume":"7","author":"CA Green","year":"2015","unstructured":"Green CA, Scarselli E, Sande CJ, Thompson AJ, de Lara CM, Taylor KS, et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med. 2015;7(300):126r\u2013300r. https:\/\/doi.org\/10.1126\/scitranslmed.aac5745.","journal-title":"Sci Transl Med"},{"issue":"7","key":"1470_CR96","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/mt.2016.67","volume":"24","author":"K Taipale","year":"2016","unstructured":"Taipale K, Liikanen I, Koski A, Heiskanen R, Kanerva A, Hemminki O, Oksanen M, Gr\u00f6nberg-V\u00e4h\u00e4-Koskela S, Hemminki K, Joensuu T, Hemminki A. Predictive and prognostic clinical variables in cancer patients treated with adenoviral oncolytic immunotherapy. Mol Ther. 2016;24(7):1323\u201332.","journal-title":"Mol Ther"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01470-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01470-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01470-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T12:27:17Z","timestamp":1732969637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01470-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01470-5","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"199"}}